drugset / Trial / NCT00748969
Clinical Trial of Growth Hormone in MPS I, II, and VI
Phase 2/3
Terminated
2 enrolled
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
Timeline
- Start
- 2008-11
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 0.48 mg/kg | Subcutaneous |